PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 141 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $943,886 | -38.5% | 289,537 | -0.0% | 0.00% | -50.0% |
| Q1 2024 | $1,535,283 | +21.5% | 289,677 | -0.8% | 0.00% | 0.0% |
| Q4 2023 | $1,263,774 | +68.2% | 291,868 | +2.2% | 0.00% | +100.0% |
| Q3 2023 | $751,276 | -25.5% | 285,657 | +0.0% | 0.00% | -50.0% |
| Q2 2023 | $1,008,149 | +14.1% | 285,598 | -0.2% | 0.00% | 0.0% |
| Q1 2023 | $883,918 | -27.0% | 286,060 | -0.0% | 0.00% | -33.3% |
| Q4 2022 | $1,210,467 | +79.1% | 286,165 | +0.3% | 0.00% | +50.0% |
| Q3 2022 | $676,000 | -16.2% | 285,251 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $807,000 | -1.7% | 283,940 | -0.6% | 0.00% | 0.0% |
| Q1 2022 | $821,000 | -4.9% | 285,614 | +0.5% | 0.00% | 0.0% |
| Q4 2021 | $863,000 | -54.7% | 284,073 | +4.5% | 0.00% | -50.0% |
| Q3 2021 | $1,904,000 | -9.2% | 271,923 | +18.9% | 0.00% | -20.0% |
| Q2 2021 | $2,097,000 | +41.6% | 228,708 | +49.8% | 0.01% | +25.0% |
| Q1 2021 | $1,481,000 | -5.5% | 152,631 | -0.3% | 0.00% | 0.0% |
| Q4 2020 | $1,568,000 | -12.8% | 153,132 | -14.2% | 0.00% | -20.0% |
| Q3 2020 | $1,799,000 | +14.9% | 178,408 | +18.8% | 0.01% | 0.0% |
| Q2 2020 | $1,566,000 | +24.3% | 150,176 | +0.6% | 0.01% | 0.0% |
| Q1 2020 | $1,260,000 | -4.7% | 149,344 | -1.3% | 0.01% | +25.0% |
| Q4 2019 | $1,322,000 | +12.7% | 151,280 | +38.7% | 0.00% | +33.3% |
| Q3 2019 | $1,173,000 | +615.2% | 109,107 | +738.1% | 0.00% | +200.0% |
| Q2 2019 | $164,000 | -89.2% | 13,018 | -66.9% | 0.00% | -80.0% |
| Q1 2019 | $1,517,000 | +363.9% | 39,290 | +157.3% | 0.01% | +400.0% |
| Q4 2018 | $327,000 | +861.8% | 15,269 | +1919.7% | 0.00% | – |
| Q3 2018 | $34,000 | -95.6% | 756 | -94.2% | 0.00% | -100.0% |
| Q2 2018 | $771,000 | -35.0% | 13,049 | -25.2% | 0.00% | -40.0% |
| Q1 2018 | $1,187,000 | -27.5% | 17,447 | +5.3% | 0.01% | -16.7% |
| Q4 2017 | $1,638,000 | +539.8% | 16,575 | +674.5% | 0.01% | +500.0% |
| Q3 2017 | $256,000 | +573.7% | 2,140 | +326.3% | 0.00% | – |
| Q3 2015 | $38,000 | -90.3% | 502 | -85.1% | 0.00% | -100.0% |
| Q2 2015 | $393,000 | -59.6% | 3,367 | -18.2% | 0.00% | -50.0% |
| Q1 2015 | $972,000 | +49.8% | 4,117 | +20.0% | 0.01% | +33.3% |
| Q4 2014 | $649,000 | – | 3,432 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 507,500 | $121,074,000 | 24.90% |
| BB BIOTECH AG | 476,991 | $113,796,000 | 4.63% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $1,356,668,000 | 3.35% |
| WEATHERBIE CAPITAL, LLC | 101,055 | $24,109,000 | 2.26% |
| Avalon Global Asset Management LLC | 16,000 | $3,817,000 | 2.24% |
| Redmile Group, LLC | 51,025 | $12,173,000 | 1.41% |
| Fernwood Investment Management, LLC | 6,700 | $1,598,000 | 1.38% |
| Iguana Healthcare Management, LLC | 10,000 | $2,386,000 | 1.27% |
| LMR Partners LLP | 56,632 | $13,510,000 | 1.08% |
| FRANKLIN STREET ADVISORS INC /NC | 21,990 | $5,246,000 | 1.00% |